We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal

Download Mobile App





New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases

By HospiMedica International staff writers
Posted on 19 Dec 2022
Print article
Image: Detecting SARS-CoV-2 with a new Quenchbody immunosensor (Photo courtesy of Tokyo Tech)
Image: Detecting SARS-CoV-2 with a new Quenchbody immunosensor (Photo courtesy of Tokyo Tech)

The incredibly fast spread of COVID-19 throughout the world brought to light a very important fact: we need better methods to diagnose infectious diseases quickly and efficiently. During the early months of the pandemic, polymerase chain reaction (PCR) tests were one of the most widely used techniques to detect COVID-19. However, these viral RNA-based techniques require expensive equipment and reaction times longer than an hour, which renders them less than ideal for point-of-care testing. The limitations of PCR fueled the development of various immunoassay methods, which use specially engineered antibodies to detect SARS-CoV-2 antigens with high sensitivity in little time. Today, scientists are still improving immunoassay technology to make available tools more convenient, sensitive, and cost-effective. Against this backdrop, a team of researchers has developed a new immunosensor based on Quenchbody technology that shows great potential as a fast, inexpensive, and convenient tool to detect SARS-CoV-2. This highly efficient diagnostic approach will be useful not only for point-of-care testing, but also for high-throughput epidemiological studies of COVID-19 and other emerging infectious diseases.

The team of researchers at Tokyo Institute of Technology (Tokyo Tech, Tokyo, Japan) has not only developed a new Quenchbody fluorescent immunosensor that can detect SARS-CoV-2 with exceptional speed and sensitivity, but also created a simple way to greatly enhance the immunosensor's performance using a crowding agent. A Quenchbody is a molecular sensor originally developed by Professor Ueda and colleagues using antibody fragments and fluorescent tags. The antibody fragment, which can be an antigen-binding region (or 'Fab'), targets a specific viral molecule (antigen). Meanwhile, the fluorescent tags are small fluorescent dye molecules attached by a peptide linker to the Quenchbody, near the antigen-binding region. When the antigen is absent, the fluorescent tags are attracted to the Fab and intrinsic amino acids (mainly tryptophan) interact with the dyes and quench the fluorescence. However, when the antigen appears, it replaces the fluorescent tag at the Fab, causing it to move away and recover its fluorescence. Thus, in a Quenchbody test, an increase in fluorescence indicates the detection of the target antigen.

In this study, the research team developed a double-tagged Quenchbody targeting the nucleocapsid protein (N protein) of SARS-CoV-2. To take things one step further, they also tested whether various commercially available compounds could improve the immunosensor's sensitivity and detection time. In particular, adding polyethylene glycol 6000 (PEG6000) at the right concentration as a crowding agent increased performance quite significantly. To further validate their approach, the team tested their immunosensor on leftover clinical samples from COVID-19 positive patients. After careful analysis of the results, they concluded that their newly developed Quenchbody could measure N protein more easily and quantitatively than a commercial lateral flow antigen test.

"Our work shows the feasibility of using Quenchbody immunosensors as rapid and cost-efficient tools for the diagnosis and high-throughput analysis of swab samples in large-scale monitoring and epidemiological studies of COVID-19, as well as other emerging infectious diseases," said Professor Hiroshi Ueda at Tokyo Tech who led the research.

Related Links:
Tokyo Tech

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
3 Channel ECG Machine
ECG-703

Print article

Channels

Critical Care

view channel
Image: The lithium-ion battery has entirely stretchable components and stable charging and discharging capacity over time (Photo courtesy of ACS Energy Letters 2024, DOI: 10.1021/acsenergylett.4c01254)

Fully Stretchable Solid Lithium-Ion Battery Paves Way For Flexible Wearable and Implantable Devices

Electronics designed to bend and stretch require batteries that possess the same flexible characteristics. Many attempts to construct such batteries have utilized conductive fabric woven into expandable... Read more

Surgical Techniques

view channel
Image: The ExcelsiusFlex and ACTIFY 3D Total Knee System have been granted FDA 510(k) clearance (Photo courtesy of Globus Medical)

New Robotic Navigation Platform Provides Surgeons Best-In-Class Solution for Orthopedic Treatment

Globus Medical (Audubon, PA, USA) has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new robotic navigation platform, ExcelsiusFlex, tailored for total knee arthroplasty... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.... Read more

Business

view channel
Image: The Innovalve transseptal delivery system is designed to enable safe deployment of the Innovalve implant (Photo courtesy of Innovalve Bio)

Edwards Lifesciences Acquires Sheba Medical’s Innovalve Bio Medical

Edwards Lifesciences (Irvine, CA, USA), a leading company in medical innovations for structural heart disease and critical care, has acquired Innovalve Bio Medical LTD. (Ramat Gan, Israel), an early-stage... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.